Levothyroxine & Omeprazole Interaction

Omeprazole, a proton pump inhibitor (PPI), can reduce the gastrointestinal absorption of levothyroxine, potentially leading to subtherapeutic thyroid hormone levels and clinical hypothyroidism in patients who were previously well-controlled ^[1]. Levothyroxine requires an acidic gastric environment for optimal dissolution and absorption, and omeprazole's profound acid suppression (raising gastric pH from 1–2 to 4–6) impairs this process ^[2]. This interaction affects a large number of patients, as hypothyroidism and acid-related disorders are both highly prevalent conditions that frequently coexist ^[3]. Studies suggest that 20–30% of levothyroxine-treated patients also use acid-suppressing medications ^[3]. While the interaction does not make co-administration impossible, it often necessitates levothyroxine dose increases of 20–40% to maintain target TSH levels, and patients require more frequent thyroid function monitoring during PPI initiation or discontinuation ^[2][4].

Levothyroxine (T4) tablets require gastric acid for dissolution of the tablet matrix and ionization of the thyroxine molecule, both of which are necessary for optimal absorption in the proximal small intestine ^[2]. In normal gastric conditions (pH 1–2), levothyroxine tablets dissolve rapidly and are approximately 60–80% absorbed ^[2]. Omeprazole irreversibly inhibits the hydrogen-potassium ATPase (proton pump) in gastric parietal cells, raising intragastric pH to 4–6 ^[4]. At this higher pH, levothyroxine tablet dissolution is significantly delayed, and the un-ionized form of T4 (which predominates at higher pH) is less readily absorbed across intestinal epithelium ^[2]. This reduced dissolution and altered ionization state decreases the bioavailability of levothyroxine, effectively reducing the amount of thyroid hormone that reaches the systemic circulation ^[2]. The effect is consistent across the PPI class and is most pronounced with high-dose or twice-daily PPI dosing ^[3].

Multiple studies have demonstrated the clinical impact of this interaction. A prospective crossover study showed that omeprazole co-administration increased TSH levels significantly in levothyroxine-treated patients, with some patients requiring dose increases of 37% to restore euthyroidism ^[2]. A large retrospective cohort study found that PPI initiation in levothyroxine-treated patients was associated with a significant increase in TSH above the target range within 2–3 months ^[3]. Conversely, PPI discontinuation in patients whose levothyroxine dose had been increased can lead to supraphysiologic thyroid hormone levels and thyrotoxicosis if the levothyroxine dose is not reduced ^[4]. The clinical consequences of undertreated hypothyroidism include fatigue, weight gain, cognitive impairment, depression, constipation, cold intolerance, and in severe cases, myxedema coma ^[1]. In pregnant patients, inadequate thyroid hormone replacement poses additional risks to fetal neurodevelopment ^[1].

Separate the administration of levothyroxine and omeprazole by at least 4 hours whenever possible ^[1]. The optimal approach is to take levothyroxine first thing in the morning on an empty stomach, wait at least 30–60 minutes before eating, and take omeprazole at a separate time (before lunch or dinner) ^[2]. If dosing separation is not feasible, consider switching from tablet levothyroxine to a liquid or softgel formulation (e.g., Tirosint), which does not require gastric acid for dissolution and has been shown to be less affected by PPI co-administration ^[3]. Monitor TSH 6–8 weeks after starting, stopping, or changing the dose of omeprazole, and adjust levothyroxine dose accordingly ^[4]. Patients should be educated that any change in their acid-suppressing medication may affect their thyroid medication levels ^[1].

Check TSH at baseline before adding omeprazole to levothyroxine therapy ^[1]. Recheck TSH 6–8 weeks after starting omeprazole, after any omeprazole dose change, and after omeprazole discontinuation ^[4]. Target TSH range for most adults is 0.5–4.0 mIU/L, though individual targets may vary (e.g., 0.5–2.5 mIU/L in pregnancy) ^[1]. If TSH rises above target, increase levothyroxine dose in increments of 12.5–25 mcg and recheck TSH in 6–8 weeks ^[2]. Monitor free T4 if TSH results are discordant with clinical status ^[1]. Assess for symptoms of hypothyroidism (fatigue, cold intolerance, weight gain, constipation, dry skin) and hyperthyroidism (if levothyroxine dose was previously increased for PPI co-administration and PPI is later stopped) at each visit ^[4].

If acid suppression is needed, H2-receptor antagonists (famotidine, ranitidine) cause less gastric acid suppression than PPIs and have a smaller impact on levothyroxine absorption, though some effect exists ^[3]. Antacids (calcium carbonate, aluminum hydroxide) should be separated from levothyroxine by at least 4 hours, as they can also impair absorption through direct binding ^[1]. Liquid or softgel levothyroxine formulations (Tirosint) bypass the acid-dependency of tablet dissolution and are less affected by gastric pH changes ^[3]. If omeprazole is being used for mild GERD, lifestyle modifications (weight loss, head-of-bed elevation, dietary changes) may allow dose reduction or discontinuation ^[4]. Pantoprazole has a similar acid-suppressing profile to omeprazole and presents the same interaction, so switching between PPIs does not resolve the issue ^[2].